Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Abbisko Completes $42 Million Series B Funding for Oncology Candidates

publication date: Mar 22, 2019

Abbisko Therapeutics of Shanghai completed a $42 million series B fundraising led by new investor Qiming, which it will use to start clinical trials of its oncology molecules and expand its discovery pipeline. Later this year, the company expects to start Phase I trials of its two lead candidates, a small molecule FGFR4 inhibitor for hepatocellular carcinoma (HCC) and a CSF1R inhibitor for solid tumors. Abbisko focused initially on developing therapies against validated targets for China-prevalent indications. Eventually, it will develop small molecules against novel targets. More details....

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital